Aumolertinib-based comprehensive treatment for an uncommon site of EGFR exon 20 insertion mutations with multiple metastases non-small cell lung cancer: a case report

被引：3

作者：

Deng, Youjun ^{[1
,2
]}

Yang, Chenglin ^{[1
,2
]}

Liu, Wenyi ^{[1
,2
]}

Cai, Songhua ^{[1
,2
]}

Guo, Xiaotong ^{[1
,2
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Shenzhen, Peoples R China

[2] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen, Guangdong, Peoples R China

来源：

ANTI-CANCER DRUGS | 2022年 / 33卷 / 04期

关键词：

aumolertinib; EGFR exon 20 insertion mutations; EGFR-TKI; non-small cell lung cancer; NSCLC;

D O I：

10.1097/CAD.0000000000001274

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EGFR exon 20 insertion mutation is a rare mutation subtype of EGFR mutations, with no approved treatment in China so far. The clinical treatments of advanced EGFR exon 20 insertion mutations in non-small cell lung cancer (NSCLC) are mainly based on EGFR-TKI, chemotherapy, ICI, and other therapies. However, the efficacy is not satisfactory. Aumolertinib is the third-generation EGFR-TKI independently developed in China, which has shown excellent efficacy and safety in phase 2 and 3 clinical trials. This study aimed to share a case of applying aumolertinib as the core combined with other treatments for a patient with multiple metastases in NSCLC with an uncommon site of EGFR exon 20 insertion mutations. The comprehensive treatment benefited the patient in terms of 10 months of progression-free survival and a significant improvement in quality of life. We discussed whether we could further explore the potential of aumolertinib in treating EGFR exon 20 insertion mutations through this case report.

引用

页码：406 / 412

页数：7

共 10 条

[1] Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea [J].